|Bid||108.61 x 2200|
|Ask||108.62 x 1000|
|Day's range||107.75 - 109.08|
|52-week range||79.11 - 121.53|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||29.32|
|Earnings date||29 Oct 2021|
|Forward dividend & yield||5.20 (4.76%)|
|Ex-dividend date||14 Oct 2021|
|1y target est||127.01|
The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...
The results from phase 3 clinical trials suggest that Rinvoq could be an effective treatment for patients.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.